Q32 Bio (QTTB)

• Market cap: $19.4M
• 1 day: -5.92%
• 5 days: -19.70%
• 1 month: -3.64%
• 3 months: -50.62%
• 6 months: -96.63%
• Year to date: -53.91%
• 1 year: -94.52%
• 5 years: -98.66%
• 10 years: -99.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Employees: 42

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

120% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 10

86% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 21

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

25% more funds holding

Funds holding: 72 [Q3] → 90 (+18) [Q4]

14.75% more ownership

Funds ownership: 75.53% [Q3] → 90.28% (+14.75%) [Q4]

88% less call options, than puts

Call options by funds: $62K | Put options by funds: $498K

91% less capital invested

Capital invested by funds: $406M [Q3] → $37.8M (-$368M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 89% upside
• Avg. target: $7.33 361% upside
• High target: $15 843% upside

3 analyst ratings

• positive: 0 0%
• neutral: 3 100%
• negative: 0 0%

Wells Fargo Derek Archila 48% 1-year accuracy 15 / 31 met price target	843% upside $15	Equal-Weight Maintained	12 Mar 2025
BMO Capital Etzer Darout 30% 1-year accuracy 10 / 33 met price target	89% upside $3	Market Perform Downgraded	11 Feb 2025
Piper Sandler Christopher Raymond 22% 1-year accuracy 6 / 27 met price target	152% upside $4	Neutral Downgraded	11 Feb 2025